LivingGLP1
Study S002808

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque

ClinicalTrials.gov record

Registration

Registration
NCT07050134
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Status
ENROLLING_BY_INVITATION
Enrollment
40
Start
2025-07-01
Primary completion
2026-12-31
Lead sponsor
Junbo Ge
Conditions
Hypertriglyceridemia; Carotid Atherosclerotic Plaques
Interventions
DRUG:DR10624 Injection；; DRUG:DR10624 Injection Placebo (referred to as placebo)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in carotid intima-media thickness (IMT) from baseline at treatment week 24 (W24). [24weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0029822Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber E, Frontiers in endocrinology
2022PreclinicalPMID 35547006DOIregistry reference BACKGROUND:35547006